Stockreport

Immunome: AL102 And Other Established Protein Targets Could Drive Value [Seeking Alpha]

Immunome, Inc.  (IMNM) 
PDF The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid t [Read more]